Breast Cancer News
In this section, access cutting-edge news about newly diagnosed breast cancer including treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
LONDON (Reuters) - Breast cancer patients who take the generic drug tamoxifen for five years are less likely to see their cancer return than those who take it for only two years, according to a large long-term study by British scientists.
NEW YORK (Reuters Health) - Older women who are diagnosed with early-stage breast cancer can expect to live just as long as peers without breast cancer, according to a new study.
Sentinel lymph node dissection was as effective as axillary lymph node surgery at lengthening lives but caused fewer painful side effects in this landmark study of women with invasive, early-stage breast cancer.
Early results from the Neo-ALTTO show that two medicines used together before surgery substantially increased response rates in HER2 positive early-stage breast cancer.
Results from two studies presented at the San Antonio Breast Cancer Symposium (SABCS) show no association between CYP2D6 levels and tamoxifen effectiveness in postmenopausal women.
NEW YORK (Reuters Health) - Women treated for breast cancer with radiation therapy are more likely to die from heart disease 20 years or more down the line than women who don't get radiation, according to a new study.
The PAL Trial, announced at the 2010 San Antonio Breast Cancer Symposium, showed that women whose lymph nodes are removed during breast cancer surgery may safely lift weights of 1 to 2 pounds without increasing their chances for developing lymphedema.
NEW YORK (Reuters Health) - A new radiation treatment for breast cancer is becoming increasingly popular despite lack of good evidence, at least among well-insured Medicare patients, U.S. researchers say,.
LOS ANGELES (Reuters) - Combining experimental antibody drug pertuzumab with Herceptin, an antibody first approved in 1998, and chemotherapy shrank tumors in nearly half of newly diagnosed breast cancer patients treated in a clinical trial.
NEW YORK (Reuters) - The Novartis osteoporosis drug Zometa failed to improve disease free survival of early breast cancer patients in a large clinical trial, but some benefit was observed in older patients who took the medicine, researchers said.